Eisai must have faith in Belviq because I have seen several commercials and it looks like they are advertising much more aggressively then when they first started.
I think this spend will growhe segment, but only a fraction of that money will grow Belviq. We need better data to differentiate our drug.
Eisai must have the data that says the advertising is worth it otherwise I can't imagine them spending additional dollars.
You do have data to differentiate yourselves. The data is the least effective weight loss drug of the 3 now that C us here.
Obviously Eisai is seeing a response to its direct marketing for Belviq. If they didn't they would not be increasing the ad spend. Therefore, Eisai sees a direct correlation to ad spend and an increase in sales for Belviq. Enough said.
Tonic, placebo label is 11 pages too you big dummy. The reason it's only 11 pages is because they list all the patients it's good for and all the advantages it has vs the competition. You dummy